Clinical trial

A Pilot Phase II Study Evaluating the Role of Chlorine Dioxide on Mucositis for Patients Undergoing Head and Neck Radiotherapy

Name
1712123818
Description
This pilot randomized phase II trial studies who well chlorine dioxide sterilization works in reducing oral mucositis in patients with stage I-IV head and neck cancer who are undergoing radiotherapy. Chlorine dioxide sterilization may help to treat oral mucositis.
Trial arms
Trial start
2019-02-14
Estimated PCD
2022-11-07
Trial end
2022-11-07
Status
Terminated
Phase
Early phase I
Treatment
Chlorine Dioxide Sterilization
Given via oral rinse
Arms:
Arm I (chlorine dioxide sterilization)
Other names:
Chlorine Dioxide
Laboratory Biomarker Analysis
Correlative studies
Arms:
Arm I (chlorine dioxide sterilization), Arm II (placebo)
Placebo
Given via oral rinse
Arms:
Arm II (placebo)
Other names:
placebo therapy, PLCB, sham therapy
Size
14
Primary endpoint
Incidence of Severe Oral Mucositis (OM) (>= World Health Organization [WHO] Mucositis Scale Grade 3)
Up to 30 days post radiotherapy
Eligibility criteria
Inclusion Criteria: * Able to provide properly obtained written informed consent * Pathologically-confirmed diagnosis of head and neck malignancy (stage I-IV) * Planned to receive high dose RT \>= 50 gray (Gy) to visualizable oral cavity and/or oropharyngeal mucosa, with or without administration of concurrent systemic therapy * Karnofsky performance status of \>= 60, within 45 days of registration * Hematocrit (Hct) \> 20 within 90 days of registration to the study * Normal cognition and willingness to complete OMWQ and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTAE) forms at each designated time point along with oral rinse diary * Life expectancy \>= 3 months * Willing to tolerate oral rinsing for 30 second intervals * Negative serum pregnancy test in females of childbearing age * Must be willing to use an effective form of birth control if of child bearing potential Exclusion Criteria: * Known hypersensitivity to chlorine dioxide products * Chlorine dioxide product usage within the past 7 days prior to registration for this study * Utilization of any antibiotic medications (topical or systemic) within past 7 days prior to registration for this study * Utilization of daily anti-inflammatory or corticosteroid medication (topical or systemic) for chronic indication other than daily low dose aspirin (81 mg) * Sjogrens disease * Medically documented glucose-6-phosphate dehydrogenase (G6PD) deficiency * Baseline hematocrit =\< 20% * Planned daily RT of less than 5 weeks duration * Known history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) * Current pregnancy
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 14, 'type': 'ACTUAL'}}
Updated at
2024-03-20

1 organization

1 product

1 indication